Business
GeneDx Announces Completion of Fabric Genomics Acquisition
Closing unlocks the next phase of genomic medicine, enabling an end-to-end centralized and decentralized model for offering clinically-actionable genomic
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\nClosing unlocks the next phase of genomic medicine, enabling an end-to-end centralized and decentralized model for offering clinically-actionable genomic insights at a global scale\n\n GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powered by centralized intelligence to set the standard of care across the globe.\n\n“Healthcare is at an inflection point where genomic insights must be integrated into standard care to improve outcomes and reduce costs,” said Katherine Stueland, President and CEO of GeneDx. “With Fabric Genomics now part of GeneDx, we’re uniquely positioned to deliver earlier and more accurate diagnoses worldwide, from NICUs and pioneering newborn screening programs to health systems across the globe.”\n\nThe combination of GeneDx’s industry leading exome and genome testing and unmatched rare disease data asset with Fabric Genomics’ advanced AI interpretation services establishes a new ecosystem for genomic diagnostics. The integrated model offers greater flexibility for providers and health systems, enabling seamless workflow integration for both centralized and decentralized genomic services, all powered by GeneDx’s deep clinical expertise and Fabric’s advanced interpretation technology.\n\nFabric Genomics will operate independently as a subsidiary of GeneDx, continuing to drive momentum with commercial support from GeneDx. The acquisition accelerates several key growth opportunities for GeneDx:\n\n\nNICU Genomic Testing: Accelerates time-to-diagnosis for critically ill newborns with scalable genomic solutions that integrate into major health system workflows, enabling GeneDx to deliver flexible end-to-end offerings and increase access to testing.\n\n\nGenomic Newborn Screening (gNBS): Positions GeneDx to support large-scale newborn screening programs in the U.S. and globally.\n\n\nGlobal Commercial Expansion: Enables flexible, regulation-compliant models for AI-powered interpretation services across EMEA, APAC, LATAM, and more.\n\n\nPlatform Economics: Unlocks recur...